Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06851858 · ClinicalTrials.gov registry record · Phase 2

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

A Phase 2 study of Obesity and Diabetes, Type II, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
69
Enrollment target
18
Study locations

NCT06851858 is a Phase 2 study of Obesity and Diabetes, Type II that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 69 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06851858, a Phase 2 study of Obesity and Diabetes, Type II, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
69 participants
Enrollment target
18
Study locations

Study Summary

This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.

Conditions Studied

Obesity Diabetes, Type II Endocrinology

Interventions

  • DRUG AZD6234
  • DRUG Placebo to match

Study Locations (18)

Florida

  • Research Site - Doral
  • Research Site - Jacksonville
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Winter Park

Alabama

  • Research Site - Birmingham
  • Research Site - Mobile

Georgia

  • Research Site - Canton
  • Research Site - Fayetteville

Illinois

  • Research Site - Chicago
  • Research Site - Oak Brook

Kansas

  • Research Site - Newton

Kentucky

  • Research Site - Lexington

Missouri

  • Research Site - Kansas City

Nevada

  • Research Site - Las Vegas

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2025-03-12
Est. Completion 2026-05-27
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06851858

The ClinicalTrials.gov registry entry for NCT06851858 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which AZD6234 is the first listed.

NCT06851858 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Florida, Alabama, Georgia.

Frequently Asked Questions

What is clinical trial NCT06851858 about?

NCT06851858 is a clinical study titled "Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist". This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.

What is the current status of trial NCT06851858?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2025-03-12. Estimated completion is 2026-05-27.

What conditions does trial NCT06851858 study?

This clinical trial studies the following conditions: Obesity, Diabetes, Type II, Endocrinology.

What interventions are being tested in trial NCT06851858?

The interventions under investigation include: AZD6234 (DRUG), Placebo to match (DRUG).

Who is sponsoring clinical trial NCT06851858?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06851858 being conducted?

This trial has 18 study locations across Alabama, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Diabetes, Type II

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.